Published in Psychiatr Clin North Am on June 01, 2003
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) | NCT00021528
Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med (2007) 4.49
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry (2005) 3.03
A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry (2010) 2.77
Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry (2011) 2.58
Prognostic subgroups for citalopram response in the STAR*D trial. J Clin Psychiatry (2014) 2.10
Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry (2009) 2.03
Experimental design and primary data analysis methods for comparing adaptive interventions. Psychol Methods (2012) 2.01
Considerations on safety concerns about citalopram prescribing. Mayo Clin Proc (2012) 1.97
A Generalization Error for Q-Learning. J Mach Learn Res (2005) 1.97
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry (2008) 1.86
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatr Scand (2009) 1.67
15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry (2005) 1.60
Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme. Biometrics (2013) 1.46
Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study. J Affect Disord (2014) 1.39
Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry (2009) 1.35
SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet (2009) 1.32
Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry (2010) 1.29
Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med (2008) 1.28
Constructing evidence-based treatment strategies using methods from computer science. Drug Alcohol Depend (2007) 1.26
Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Compr Psychiatry (2008) 1.20
Explaining patients' beliefs about the necessity and harmfulness of antidepressants. Ann Fam Med (2008) 1.18
Interactive model building for Q-learning. Biometrika (2014) 1.14
Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol (2011) 1.14
Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. J Clin Child Adolesc Psychol (2008) 1.11
Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. J Psychiatr Res (2006) 1.11
The relationship between the therapeutic alliance and treatment outcome in two distinct psychotherapies for chronic depression. J Consult Clin Psychol (2013) 1.09
CYP2C19 variation and citalopram response. Pharmacogenet Genomics (2011) 1.09
Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics (2009) 1.06
Enhancing validity in co-occurring disorders treatment research. Schizophr Bull (2006) 1.06
Screening Experiments for Developing Dynamic Treatment Regimes. J Am Stat Assoc (2009) 1.04
Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res (2008) 1.03
Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm (Vienna) (2008) 1.03
The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS One (2014) 1.02
Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report. Soc Psychiatry Psychiatr Epidemiol (2007) 1.01
The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology (2010) 0.98
Cognitive therapy for anxious depression in STAR(*) D: what have we learned? J Affect Disord (2012) 0.97
Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics (2009) 0.97
Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. J Consult Clin Psychol (2008) 0.97
SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet (2009) 0.95
A multiple imputation strategy for sequential multiple assignment randomized trials. Stat Med (2014) 0.95
Moving to Second-Stage Treatments Faster: Identifying Midtreatment Tailoring Variables for Youth with Anxiety Disorders. J Clin Child Adolesc Psychol (2015) 0.92
Penalized Q-Learning for Dynamic Treatment Regimens. Stat Sin (2015) 0.91
Adapted behavior therapy for persistently depressed primary care patients: an open trial. Behav Modif (2009) 0.91
Screening for major depression in private practice. J Psychiatr Pract (2009) 0.90
A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res (2013) 0.90
Patient treatment preference as a predictor of response and attrition in treatment for chronic depression. Depress Anxiety (2012) 0.89
Assessing physicians' use of treatment algorithms: Project IMPACTS study design and rationale. Contemp Clin Trials (2006) 0.88
Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis. Prim Care Companion J Clin Psychiatry (2007) 0.88
The STAR*D Trial: It Is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression. Can J Psychiatry (2015) 0.88
Quest for biomarkers of treatment-resistant depression: shifting the paradigm toward risk. Front Psychiatry (2013) 0.87
STAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby! Can J Psychiatry (2015) 0.87
Assessing anxious features in depressed outpatients. Int J Methods Psychiatr Res (2011) 0.86
Identifying risk for attrition during treatment for depression. Psychother Psychosom (2009) 0.86
The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry (2015) 0.85
Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology (2007) 0.85
Psychopharmacological Practice: The DSM Versus The Brain. Mens Sana Monogr (2013) 0.85
Detecting critical decision points in psychotherapy and psychotherapy + medication for chronic depression. J Consult Clin Psychol (2013) 0.85
Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J Affect Disord (2013) 0.84
Genetic predictors of risk and resilience in psychiatric disorders: a cross-disorder genome-wide association study of functional impairment in major depressive disorder, bipolar disorder, and schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2013) 0.84
Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. J Womens Health (Larchmt) (2013) 0.84
Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression. PLoS One (2014) 0.83
Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up. Acta Psychiatr Scand (2014) 0.83
Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial. Depress Anxiety (2013) 0.83
Development and validation of the Individual Burden of Illness Index for Major Depressive Disorder (IBI-D). Adm Policy Ment Health (2013) 0.83
A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol (2015) 0.82
PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics (2011) 0.82
Construct development: The Suicide Trigger Scale (STS-2), a measure of a hypothesized suicide trigger state. BMC Psychiatry (2010) 0.82
MDPs with Non-Deterministic Policies. Adv Neural Inf Process Syst (2009) 0.82
Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci (2010) 0.82
A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises. Psychiatry Investig (2014) 0.82
The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. Menopause (2010) 0.81
Bipolar polygenic loading and bipolar spectrum features in major depressive disorder. Bipolar Disord (2014) 0.80
What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? Depress Anxiety (2011) 0.79
A computerized decision support system for depression in primary care. Prim Care Companion J Clin Psychiatry (2009) 0.78
Use of functional imaging across clinical phases in CNS drug development. Transl Psychiatry (2013) 0.78
The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: a STAR*D report. J Womens Health (Larchmt) (2013) 0.78
Translating Science Into Service: Lessons Learned From the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. Prim Care Companion J Clin Psychiatry (2007) 0.78
Social problem solving and depressive symptoms over time: a randomized clinical trial of cognitive-behavioral analysis system of psychotherapy, brief supportive psychotherapy, and pharmacotherapy. J Consult Clin Psychol (2011) 0.78
Review of Cohort Studies for Mood Disorders. Psychiatry Investig (2016) 0.77
Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients. Can J Psychiatry (2016) 0.77
The strategy of combining antidepressants in the treatment of major depression: clinical experience in spanish outpatients. Depress Res Treat (2011) 0.77
Sparse generalized functional linear model for predicting remission status of depression patients. Pac Symp Biocomput (2014) 0.77
The effectiveness of antidepressant monotherapy in a naturalistic outpatient setting. Prim Care Companion CNS Disord (2012) 0.76
Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat (2008) 0.76
Patient-reported outcomes before and after treatment of major depressive disorder. Dialogues Clin Neurosci (2014) 0.76
Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. Ann Gen Psychiatry (2007) 0.76
Metabolomic biosignature differentiates melancholic depressive patients from healthy controls. BMC Genomics (2016) 0.76
Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Med J (2015) 0.76
Dysfunctional attitudes as a moderator of pharmacotherapy and psychotherapy for chronic depression. J Psychiatr Res (2012) 0.76
Prediction of treatment outcomes in psychiatry--where do we stand ? Dialogues Clin Neurosci (2014) 0.76
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Res Notes (2014) 0.76
Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression? Depress Anxiety (2011) 0.76
Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies. Prim Care Companion CNS Disord (2012) 0.75
National trends in prayer use as a coping mechanism for depression: changes from 2002 to 2007. J Relig Health (2013) 0.75
Improved mood and remission of symptoms in long-term major depression using vagus nerve stimulation. MedGenMed (2007) 0.75
Models for treating depression in specialty medical settings: a narrative review. Gen Hosp Psychiatry (2015) 0.75
Sequential advantage selection for optimal treatment regime. Ann Appl Stat (2016) 0.75
Do depressed patients with diabetes experience more side effects when treated with CitalopramThan their counterparts without diabetes? a STAR*D study. Prim Care Companion J Clin Psychiatry (2009) 0.75
Patient-reported functioning in major depressive disorder. Ther Adv Chronic Dis (2016) 0.75
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 34.83
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry (2003) 13.60
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet (2008) 10.49
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
Maintenance treatment of major depression in old age. N Engl J Med (2006) 7.61
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet (2003) 5.75
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry (2007) 5.59
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Exercise treatment for depression: efficacy and dose response. Am J Prev Med (2005) 4.99
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry (2005) 4.84
Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry (2006) 4.37
Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up. Psychosom Med (2003) 4.30
Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry (2002) 4.08
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med (2001) 4.07
How and why criteria defining moderators and mediators differ between the Baron & Kenny and MacArthur approaches. Health Psychol (2008) 4.04
Moderators of treatment outcomes: clinical, research, and policy importance. JAMA (2006) 4.03
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry (2004) 3.84
The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry (2008) 3.82
Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80
Development of a computerized adaptive test for depression. Arch Gen Psychiatry (2012) 3.77
Translating the Diabetes Prevention Program lifestyle intervention for weight loss into primary care: a randomized trial. JAMA Intern Med (2013) 3.69
A new approach to integrating data from multiple informants in psychiatric assessment and research: mixing and matching contexts and perspectives. Am J Psychiatry (2003) 3.66
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med (2009) 3.65
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol (2008) 3.65
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2003) 3.60
DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. Am J Psychiatry (2013) 3.58
Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA (2007) 3.44
Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2004) 3.43
Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry (2008) 3.40
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (2007) 3.38
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry (2011) 3.34
The future of psychiatry as clinical neuroscience. Acad Med (2009) 3.31
Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry (2005) 3.23
Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry (2010) 3.14
Estimating Individualized Treatment Rules Using Outcome Weighted Learning. J Am Stat Assoc (2012) 3.13
Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry (2005) 3.05
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry (2005) 3.03
Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol (2007) 2.99
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry (2007) 2.87
Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry (2004) 2.87
Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 2.85
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry (2014) 2.82
Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry (2013) 2.80
Parietal cortex and representation of the mental Self. Proc Natl Acad Sci U S A (2004) 2.73
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A (2006) 2.72
Improving clinical trials: American Society of Clinical Psychopharmacology recommendations. Arch Gen Psychiatry (2002) 2.70
Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry (2006) 2.69